HIVE vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HIVE exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and deteriorating operational efficiency. While the company shows explosive revenue growth (218.60% YoY) and trades slightly below book value (P/B 0.90), these are offset by deep negative profit margins (-48.63%) and a complete lack of technical momentum (Technical Trend: 0/100). The massive divergence between the 'Strong Buy' analyst consensus and the actual financial health suggests a speculative valuation based on future potential rather than current performance.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
HIVE vs JPM: Head-to-Head Comparison
This page compares HIVE Digital Technologies Ltd. (HIVE) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.